(Morning Ticker) – Recently we reported on the FDA’s decision to approve Entresto, a new drug from Novartis that has shown an astonishing 20 percent reduction in mortality and hospitalization rates in patients with heart disease, something that has resulted in an excitement from the medical community. But what may be lost in the shuffle […]